Britain's GlaxoSmithKline PLC says it has completed its $3.6 billion acquisition of US biotech company Human Genome Sciences.
In a statement today, the pharmaceutical and consumer goods group says all outstanding shares were bought for $14.25 each in cash.
Human Genome Sciences, based in Rockville, Md., agreed to the acquisition last month after GSK raised its bid price from $13 a share.
Under the agreement, GSK gains full ownership of two experimental drugs plus Human Genome's only marketed medicine, Benlysta.
That is the first new drug approved in about 50 years for lupus, a chronic immune disorder.
GSK expects the deal to add to core earnings from next year and to produce at least $200 million in cost savings by 2015.
